Review



human anti cd47 apc conjugated antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    R&D Systems human anti cd47 apc conjugated antibody
    Fig. 1 A Schematic representation of the preparation of rtPA-loaded CSM derived from platelets. B Representative mean hydrodynamic diameter of CSM and CSM@rtPA before and after lyophilization (CSM@rtPA/L) process measured by DLS. Data represent mean ± SEM (n = 3, independent samples). C Representative mean diameter of CSM and CSM@rtPA before and after lyophilization process (CSM@rtPA/L) measured by NTA. Data represent mean ± SEM (n = 3, independent samples). D Representative STEM-in SEM images of CSM@rtPA negatively stained with uranyl acetate. Scale bars: 200 nm. E Loading capacity of rtPA encapsulated in CSM samples. Data represent mean ± SEM (n = 3, independent samples). F Representative density plots and quantitative analysis of CSM and CSM@rtPA measured by FC. Scatter density plots of Green fluorescence signal (Green-B channel, rtPA channel) versus Red fluorescence signal (Red-R channel, CellMask DeepRed channel) for CSM, CSM@rtPA, and CSM@rtPA sample after labeling with CellMask Deep Red for lipid staining. Mean fluorescence intensities (MFI) for Green-B channel (D) and Red-R channel. Data represent mean ± SEM (n = 3, independent samples). G. Schematic representation of platelets and platelet-derived CSM surface proteins studied by <t>APC-fluorescently</t> labeled antibodies: anti-hCD47 Ab and anti-hCD42b/GPlba Ab. In vitro Ab binding to platelets and CSM@rtPA before and after lyophilization process. Representative MFI histogram of Red-R channel (APC signal) for platelets, CSM@rtPA and CSM@rtPA/L samples after incubation with <t>APC-anti-CD47</t> and APC-anti-CD42b/GPIbα antibodies
    Human Anti Cd47 Apc Conjugated Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/Human+CD47+APC-conjugated+Antibody/pm38166940-252-3-9
    Average 92 stars, based on 3 article reviews
    human anti cd47 apc conjugated antibody - by Bioz Stars, 2026-11
    92/100 stars

    Images

    1) Product Images from "Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke."

    Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke.

    Journal: Journal of nanobiotechnology

    doi: 10.1186/s12951-023-02206-5

    Fig. 1 A Schematic representation of the preparation of rtPA-loaded CSM derived from platelets. B Representative mean hydrodynamic diameter of CSM and CSM@rtPA before and after lyophilization (CSM@rtPA/L) process measured by DLS. Data represent mean ± SEM (n = 3, independent samples). C Representative mean diameter of CSM and CSM@rtPA before and after lyophilization process (CSM@rtPA/L) measured by NTA. Data represent mean ± SEM (n = 3, independent samples). D Representative STEM-in SEM images of CSM@rtPA negatively stained with uranyl acetate. Scale bars: 200 nm. E Loading capacity of rtPA encapsulated in CSM samples. Data represent mean ± SEM (n = 3, independent samples). F Representative density plots and quantitative analysis of CSM and CSM@rtPA measured by FC. Scatter density plots of Green fluorescence signal (Green-B channel, rtPA channel) versus Red fluorescence signal (Red-R channel, CellMask DeepRed channel) for CSM, CSM@rtPA, and CSM@rtPA sample after labeling with CellMask Deep Red for lipid staining. Mean fluorescence intensities (MFI) for Green-B channel (D) and Red-R channel. Data represent mean ± SEM (n = 3, independent samples). G. Schematic representation of platelets and platelet-derived CSM surface proteins studied by APC-fluorescently labeled antibodies: anti-hCD47 Ab and anti-hCD42b/GPlba Ab. In vitro Ab binding to platelets and CSM@rtPA before and after lyophilization process. Representative MFI histogram of Red-R channel (APC signal) for platelets, CSM@rtPA and CSM@rtPA/L samples after incubation with APC-anti-CD47 and APC-anti-CD42b/GPIbα antibodies
    Figure Legend Snippet: Fig. 1 A Schematic representation of the preparation of rtPA-loaded CSM derived from platelets. B Representative mean hydrodynamic diameter of CSM and CSM@rtPA before and after lyophilization (CSM@rtPA/L) process measured by DLS. Data represent mean ± SEM (n = 3, independent samples). C Representative mean diameter of CSM and CSM@rtPA before and after lyophilization process (CSM@rtPA/L) measured by NTA. Data represent mean ± SEM (n = 3, independent samples). D Representative STEM-in SEM images of CSM@rtPA negatively stained with uranyl acetate. Scale bars: 200 nm. E Loading capacity of rtPA encapsulated in CSM samples. Data represent mean ± SEM (n = 3, independent samples). F Representative density plots and quantitative analysis of CSM and CSM@rtPA measured by FC. Scatter density plots of Green fluorescence signal (Green-B channel, rtPA channel) versus Red fluorescence signal (Red-R channel, CellMask DeepRed channel) for CSM, CSM@rtPA, and CSM@rtPA sample after labeling with CellMask Deep Red for lipid staining. Mean fluorescence intensities (MFI) for Green-B channel (D) and Red-R channel. Data represent mean ± SEM (n = 3, independent samples). G. Schematic representation of platelets and platelet-derived CSM surface proteins studied by APC-fluorescently labeled antibodies: anti-hCD47 Ab and anti-hCD42b/GPlba Ab. In vitro Ab binding to platelets and CSM@rtPA before and after lyophilization process. Representative MFI histogram of Red-R channel (APC signal) for platelets, CSM@rtPA and CSM@rtPA/L samples after incubation with APC-anti-CD47 and APC-anti-CD42b/GPIbα antibodies

    Techniques Used: Derivative Assay, Lyophilization, Staining, Fluorescence, Labeling, In Vitro, Binding Assay, Incubation

    Related Articles

    Incubation:

    Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke
    Article Snippet: .. Then, uorescently antibodies, human anti-CD47 APC conjugated Antibody (FAB4670A, R&D Systems) and human antiCD42b/GPlbα APC conjugated Antibody (FAB4067A, R&D systems) were incubated with platelets and with CSMs (10 μL of antibody stock solution /106 cells) and the samples were analyzed by ow cytometer. .. A Guava easyCyteTM HT ow cytometer (Luminex), using a blue laser emitting at 488 nm and a red laser emitting at 642 nm was used.

    Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke.
    Article Snippet: .. Then, fluorescently antibodies, human anti-CD47 APC conjugated Antibody (FAB4670A, R&D Systems) and human antiCD42b/GPlbα APC conjugated Antibody (FAB4067A, R&D systems) were incubated with platelets and with CSMs (10 μL of antibody stock solution /106 cells) and the samples were analyzed by flow cytometer. .. A CytoFLEX flow cytometer (Beckman Coulter), using a blue laser emitting at 488 nm and a red laser emitting at 642 nm was used.

    Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke
    Article Snippet: .. Then, fluorescently antibodies, human anti-CD47 APC conjugated Antibody (FAB4670A, R&D Systems) and human antiCD42b/GPlbα APC conjugated Antibody (FAB4067A, R&D systems) were incubated with platelets and with CSMs (10 μL of antibody stock solution /10 6 cells) and the samples were analyzed by flow cytometer. .. A CytoFLEX flow cytometer (Beckman Coulter), using a blue laser emitting at 488 nm and a red laser emitting at 642 nm was used.

    Cytometry:

    Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke
    Article Snippet: .. Then, uorescently antibodies, human anti-CD47 APC conjugated Antibody (FAB4670A, R&D Systems) and human antiCD42b/GPlbα APC conjugated Antibody (FAB4067A, R&D systems) were incubated with platelets and with CSMs (10 μL of antibody stock solution /106 cells) and the samples were analyzed by ow cytometer. .. A Guava easyCyteTM HT ow cytometer (Luminex), using a blue laser emitting at 488 nm and a red laser emitting at 642 nm was used.

    Flow Cytometry:

    Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke.
    Article Snippet: .. Then, fluorescently antibodies, human anti-CD47 APC conjugated Antibody (FAB4670A, R&D Systems) and human antiCD42b/GPlbα APC conjugated Antibody (FAB4067A, R&D systems) were incubated with platelets and with CSMs (10 μL of antibody stock solution /106 cells) and the samples were analyzed by flow cytometer. .. A CytoFLEX flow cytometer (Beckman Coulter), using a blue laser emitting at 488 nm and a red laser emitting at 642 nm was used.

    Article Title: Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke
    Article Snippet: .. Then, fluorescently antibodies, human anti-CD47 APC conjugated Antibody (FAB4670A, R&D Systems) and human antiCD42b/GPlbα APC conjugated Antibody (FAB4067A, R&D systems) were incubated with platelets and with CSMs (10 μL of antibody stock solution /10 6 cells) and the samples were analyzed by flow cytometer. .. A CytoFLEX flow cytometer (Beckman Coulter), using a blue laser emitting at 488 nm and a red laser emitting at 642 nm was used.



    Similar Products

    94
    Sino Biological recombinant human cd47 protein rhcd47
    Recombinant Human Cd47 Protein Rhcd47, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/Human+CD47+Protein/10__1038_slash_s41467___026___77779___4-303-11-16
    Average 94 stars, based on 1 article reviews
    recombinant human cd47 protein rhcd47 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Bio X Cell anti cd47 antibody
    Anti Cd47 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/InVivoMAb+anti-mouse+human+rat+CD47/pm42901146-411-48-52
    Average 95 stars, based on 1 article reviews
    anti cd47 antibody - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Bio X Cell invivomab anti mouse cd47 antibody
    Invivomab Anti Mouse Cd47 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/InVivoMAb+anti-mouse+CD47/pm42901146-306-6-10
    Average 96 stars, based on 1 article reviews
    invivomab anti mouse cd47 antibody - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    Bio X Cell anti mouse cd47 monoclonal antibody
    Anti Mouse Cd47 Monoclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/InVivoPlus+anti-mouse+human+rat+CD47/pm42849672-120-21-25
    Average 95 stars, based on 1 article reviews
    anti mouse cd47 monoclonal antibody - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Bio X Cell anti mouse cd47 monoclonal antibodies
    Real‐time monitoring of tumor progression and <t>anti‐CD47</t> therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).
    Anti Mouse Cd47 Monoclonal Antibodies, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/InVivoMAb+anti-mouse+CD47/pmc13650256-56-17-29
    Average 96 stars, based on 1 article reviews
    anti mouse cd47 monoclonal antibodies - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    Santa Cruz Biotechnology anti cd47 antibodies
    Real‐time monitoring of tumor progression and <t>anti‐CD47</t> therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).
    Anti Cd47 Antibodies, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/CD47+Antibody/pm42849672-99-10-12
    Average 95 stars, based on 1 article reviews
    anti cd47 antibodies - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    96
    Bio X Cell anti mouse cd47 antibody
    Real‐time monitoring of tumor progression and <t>anti‐CD47</t> therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).
    Anti Mouse Cd47 Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/InVivoMAb+anti-mouse+CD47/pm42843530-144-7-12
    Average 96 stars, based on 1 article reviews
    anti mouse cd47 antibody - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology mouse cd47
    Real‐time monitoring of tumor progression and <t>anti‐CD47</t> therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).
    Mouse Cd47, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/Recombinant+Mouse+CD47%2FIAP%2FOA3+Protein/pm42833217-406-40-44
    Average 94 stars, based on 1 article reviews
    mouse cd47 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    ABclonal Biotechnology human cd47
    Real‐time monitoring of tumor progression and <t>anti‐CD47</t> therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).
    Human Cd47, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/Recombinant+Mouse+CD47%2FIAP%2FOA3+Protein/pm42833217-406-34-38
    Average 94 stars, based on 1 article reviews
    human cd47 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Santa Cruz Biotechnology cd47 antibody b6h12 alexa fluor 594
    Real‐time monitoring of tumor progression and <t>anti‐CD47</t> therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).
    Cd47 Antibody B6h12 Alexa Fluor 594, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd47/CD47+Antibody/pm42785083-46-0-11
    Average 95 stars, based on 1 article reviews
    cd47 antibody b6h12 alexa fluor 594 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    Real‐time monitoring of tumor progression and anti‐CD47 therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).

    Journal: Cancer Medicine

    Article Title: In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer

    doi: 10.1002/cam4.72232

    Figure Lengend Snippet: Real‐time monitoring of tumor progression and anti‐CD47 therapeutic efficiency. (A) Female BALB/c mice aged 8–10 weeks were implanted with dorsal skinfold window chambers. 4T1_PB3R‐RFP TNBC cells were transplanted into the subcutaneous tissue, and tumors were monitored using intravital imaging. (B) Detailed visualization of angiogenesis and tumor nodule formation in TNBC skinfold models compared with the isotype control group. (C, D) Conventional whole‐body bioluminescence imaging of mice bearing 4T1_PB3R‐RFP‐luc tumors revealed considerably decreased signals following anti‐CD47 immunotherapy administered over 5 days, beginning on day 9 for 5 days ( n = 7, p < 0.0001, 10 mg/kg, intravenous injection). Data are presented as the mean ± standard deviation (SD).

    Article Snippet: To evaluate the performance of the in vivo immunoscoring technique for the monitoring of anti‐CD47 immunotherapy efficacy, anti‐mouse CD47 monoclonal antibodies (specifically, anti‐CD47 mAbs, clone MIAP301, Rat IgG2a, κ, BioXcell, USA) and an IgG2a mAbs isotype control (clone 2A3, Rat IgG2a, κ, BioXcell, USA) were systemically and intravenously (IV) injected at a dosage of 10 mg/kg once a day for a duration of five consecutive days.

    Techniques: Real-time Monitoring, Tissue, Imaging, Control, Injection, Standard Deviation

    In vivo and in vitro validation of TNBC targeting by Dextran‐AF680. (A–C) The signals emitted by Dextran‐AF680 at various time intervals following intravenous injections exhibited significant differences between 10 and 180 min and between 180 and 360 min. (D, E) Dextran‐AF680 can be administrated for TNBC imaging with photoacoustic tomography, and the optimal imaging time is 3 h after dextran injection, indicating its potential as an imaging probe for enhancing TNBC visualization ( n = 7, p = 0.024, p = 0.004). (F, G) Longitudinal conventional fluorescence imaging of the anti‐CD47 immunotherapeutic response, in comparison with the isotype control treatment, demonstrated a significant change in the average radiant efficiency of Dextran AF680 following 5 days of treatment ( n = 12, p = 0.0022). (H, I) An evident shift in the population of Dextran‐AF680+ and RFP+ cells was observed after anti‐CD47 mAb immunotherapies ( n = 10, p = 0.0079). Data are presented as the mean ± standard deviation (SD).

    Journal: Cancer Medicine

    Article Title: In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer

    doi: 10.1002/cam4.72232

    Figure Lengend Snippet: In vivo and in vitro validation of TNBC targeting by Dextran‐AF680. (A–C) The signals emitted by Dextran‐AF680 at various time intervals following intravenous injections exhibited significant differences between 10 and 180 min and between 180 and 360 min. (D, E) Dextran‐AF680 can be administrated for TNBC imaging with photoacoustic tomography, and the optimal imaging time is 3 h after dextran injection, indicating its potential as an imaging probe for enhancing TNBC visualization ( n = 7, p = 0.024, p = 0.004). (F, G) Longitudinal conventional fluorescence imaging of the anti‐CD47 immunotherapeutic response, in comparison with the isotype control treatment, demonstrated a significant change in the average radiant efficiency of Dextran AF680 following 5 days of treatment ( n = 12, p = 0.0022). (H, I) An evident shift in the population of Dextran‐AF680+ and RFP+ cells was observed after anti‐CD47 mAb immunotherapies ( n = 10, p = 0.0079). Data are presented as the mean ± standard deviation (SD).

    Article Snippet: To evaluate the performance of the in vivo immunoscoring technique for the monitoring of anti‐CD47 immunotherapy efficacy, anti‐mouse CD47 monoclonal antibodies (specifically, anti‐CD47 mAbs, clone MIAP301, Rat IgG2a, κ, BioXcell, USA) and an IgG2a mAbs isotype control (clone 2A3, Rat IgG2a, κ, BioXcell, USA) were systemically and intravenously (IV) injected at a dosage of 10 mg/kg once a day for a duration of five consecutive days.

    Techniques: In Vivo, In Vitro, Biomarker Discovery, Imaging, Micro-PAT, Injection, Fluorescence, Comparison, Control, Standard Deviation

    Intravital imaging of M2 macrophage targeting by Dextran‐AF680. (A) Dynamic in vivo distribution of intravenously injected Dextran‐AF680 in representative blood vessels of a skinfold TNBC model. The Dextran‐AF680 signal peaked at 3 h and dissipated from the vessels within 24 h. (B) Substantial colocalization was observed between Dextran‐AF680 targeted cells (red) and CD206‐FITC+ cells (green). (C) Antibody‐dependent cellular phagocytosis (ADCP) occured in rapid, brief waves between Dextran‐AF680‐labeled macrophages and CD47 inhibitor‐treated tumor cells in a skinfold TNBC model. (D) CD47 inhibitor‐treated cancer cells (green) were engulfed by macrophages labeled with the pan‐macrophage marker F4/80‐PE (red), underscoring the highly phagocytic nature of macrophages (scale bars, 25 μm). (E) Intravital imaging of the robust phagocytic capacity of F4/80+ macrophages (red) toward CD47 inhibitor‐treated tumor cells (green).

    Journal: Cancer Medicine

    Article Title: In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer

    doi: 10.1002/cam4.72232

    Figure Lengend Snippet: Intravital imaging of M2 macrophage targeting by Dextran‐AF680. (A) Dynamic in vivo distribution of intravenously injected Dextran‐AF680 in representative blood vessels of a skinfold TNBC model. The Dextran‐AF680 signal peaked at 3 h and dissipated from the vessels within 24 h. (B) Substantial colocalization was observed between Dextran‐AF680 targeted cells (red) and CD206‐FITC+ cells (green). (C) Antibody‐dependent cellular phagocytosis (ADCP) occured in rapid, brief waves between Dextran‐AF680‐labeled macrophages and CD47 inhibitor‐treated tumor cells in a skinfold TNBC model. (D) CD47 inhibitor‐treated cancer cells (green) were engulfed by macrophages labeled with the pan‐macrophage marker F4/80‐PE (red), underscoring the highly phagocytic nature of macrophages (scale bars, 25 μm). (E) Intravital imaging of the robust phagocytic capacity of F4/80+ macrophages (red) toward CD47 inhibitor‐treated tumor cells (green).

    Article Snippet: To evaluate the performance of the in vivo immunoscoring technique for the monitoring of anti‐CD47 immunotherapy efficacy, anti‐mouse CD47 monoclonal antibodies (specifically, anti‐CD47 mAbs, clone MIAP301, Rat IgG2a, κ, BioXcell, USA) and an IgG2a mAbs isotype control (clone 2A3, Rat IgG2a, κ, BioXcell, USA) were systemically and intravenously (IV) injected at a dosage of 10 mg/kg once a day for a duration of five consecutive days.

    Techniques: Imaging, In Vivo, Injection, Labeling, Marker

    In vivo and in vitro validation of TNBC targeting by MCP1‐FITC. (A, B) Following intravenous injection of MCP1‐FITC, fluorescence signals in TNBC tissue peaked at 4 min and rapidly declined within 2 h ( n = 6, p = 0.0313). (C, D) Ex vivo imaging of dissected organs from subcutaneous xenograft models revealed a noticeable difference in fluorescence signal intensity between TNBC tumors and normal organs at 4 min after intravenous injection of MCP1‐FITC ( n = 6, p = 0.0095). (E, F) The average radiant efficiency of MCP1‐FITC in resected TNBC tissues was quantitively compared between the anti‐CD47 monoclonal antibody (mAb) and isotype control (ISO) treatment groups ( n = 16, p = 0.0499). (G) A significant difference in the M1/M2 ratio, based on the average radiant efficiency, was observed between anti‐CD47 mAb‐treated and ISO‐treated mice ( n = 12, p = 0.0022). (H) A pronounced shift in the population of MCP1‐FITC targeted cells was observed following repeated immunotherapy. (I, J) Significant differences in the M1/M2 ratio, based on the MCP‐1 FITC+ cells, is observed between anti‐CD47 mAb‐treated and ISO‐treated mice ( n = 16, p = 0.0104), ( n = 10, p = 0.0079). (K) A correlation analysis indicated that there is a strong correlation between the flow cytometry‐derived M1/M2 ratio and the imaging‐derived M1/M2 ratio. Data are presented as the mean ± standard deviation (SD).

    Journal: Cancer Medicine

    Article Title: In Vivo Immunoscoring Technique to Monitor Anti‐ CD47 Immunotherapy Efficacy in Triple‐Negative Breast Cancer

    doi: 10.1002/cam4.72232

    Figure Lengend Snippet: In vivo and in vitro validation of TNBC targeting by MCP1‐FITC. (A, B) Following intravenous injection of MCP1‐FITC, fluorescence signals in TNBC tissue peaked at 4 min and rapidly declined within 2 h ( n = 6, p = 0.0313). (C, D) Ex vivo imaging of dissected organs from subcutaneous xenograft models revealed a noticeable difference in fluorescence signal intensity between TNBC tumors and normal organs at 4 min after intravenous injection of MCP1‐FITC ( n = 6, p = 0.0095). (E, F) The average radiant efficiency of MCP1‐FITC in resected TNBC tissues was quantitively compared between the anti‐CD47 monoclonal antibody (mAb) and isotype control (ISO) treatment groups ( n = 16, p = 0.0499). (G) A significant difference in the M1/M2 ratio, based on the average radiant efficiency, was observed between anti‐CD47 mAb‐treated and ISO‐treated mice ( n = 12, p = 0.0022). (H) A pronounced shift in the population of MCP1‐FITC targeted cells was observed following repeated immunotherapy. (I, J) Significant differences in the M1/M2 ratio, based on the MCP‐1 FITC+ cells, is observed between anti‐CD47 mAb‐treated and ISO‐treated mice ( n = 16, p = 0.0104), ( n = 10, p = 0.0079). (K) A correlation analysis indicated that there is a strong correlation between the flow cytometry‐derived M1/M2 ratio and the imaging‐derived M1/M2 ratio. Data are presented as the mean ± standard deviation (SD).

    Article Snippet: To evaluate the performance of the in vivo immunoscoring technique for the monitoring of anti‐CD47 immunotherapy efficacy, anti‐mouse CD47 monoclonal antibodies (specifically, anti‐CD47 mAbs, clone MIAP301, Rat IgG2a, κ, BioXcell, USA) and an IgG2a mAbs isotype control (clone 2A3, Rat IgG2a, κ, BioXcell, USA) were systemically and intravenously (IV) injected at a dosage of 10 mg/kg once a day for a duration of five consecutive days.

    Techniques: In Vivo, In Vitro, Biomarker Discovery, Injection, Fluorescence, Tissue, Ex Vivo, Imaging, Xenograft Assay, Control, Analysis, Flow Cytometry, Derivative Assay, Standard Deviation